For well-differentiated, low-proliferation tumors (Ki-67 < 3%), somatostatin analogs (SSAs) such as octreotide and lanreotide are typically first-line treatments, given their role in slowing tumor progression and controlling symptoms [138]. Here, MKI67 is linked to neoplasm.